lansoprazole

Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Lansoprazole sodium (Lansoprazole (sodium)) is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease.

(R)-Lansoprazole (T 168390) is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Lansoprazole sulfide (AG-177) is an active metabolite of Lansoprazole with similar activity.Lansoprazole is a proton pump inhibitor and antitubercular agent with an IC50= 0.59 µM against Mycobacterium tuberculosis.

Lansoprazole D4 (AG-1749 D4) is a deuterium labeled Lansoprazole. Lansoprazole is an inhibitor of proton pump which prevents the stomach from producing acid.

Lansoprazole Sulfide D4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 μM intracellularly and 0.46 μM in broth.Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole.

5-Hydroxy Lansoprazole Sulfide is an inhibitor of fatty acid synthase (FASN). FASN, which is responsible for de-novo synthesis of lipids, has been found to be overexpressed in cancerous tissue. 5-Hydroxy Lansoprazole Sulfide specifically inhibits enoyl reductase, and was found to more effectively inhibit FASN function than lansoprazole and was also more efficient at regulating NHEJ repair of oxidative DNA damage via PARP1.

Lansoprazole N-oxide is a potential impurity in lansoprazole bulk preparations, identified as a degradation product under acidic or basic conditions. This compound is related to lansoprazole, a proton pump inhibitor.

Lansoprazole sulfone is a metabolite of the gastric pump inhibitor Lansoprazole.

Dexlansoprazole-d4 is a deuterated compound of Dexlansoprazole. Dexlansoprazole has a CAS number of 138530-94-6. Dexlansoprazole is the R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Levolansoprazole ((S)-Lansoprazole), a proton pump inhibitor, irreversibly inhibits H+ K+-stimulated ATPase pumps in parietal cells (IC50: 5.2 μM). It also inhibits acid formation in isolated canine parietal cells (IC50: 82 μM). Both (R)- and (S)-lansoprazole are pharmacologically active with similar potencies.

5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole, a gastric proton-pump inhibitor used to treat various peptic diseases. Lansoprazole is metabolized through CYP2C19, resulting in the formation of 5-Hydroxylansoprazole[1][2].

Levolansoprazole-d4 is a deuterated compound of Levolansoprazole. Levolansoprazole has a CAS number of 138530-95-7. Levolansoprazole, a proton pump inhibitor, irreversibly inhibits H+ K+-stimulated ATPase pumps in parietal cells (IC50: 5.2 µM). It also inhibits acid formation in isolated canine parietal cells (IC50: 82 µM). Both (R)- and (S)-lansoprazole are pharmacologically active with similar potencies.

5-hydroxylansoprazole is an in vitro metabolism-dependent CYP2C19 inhibitor.

ABT-1812 is a bio-active chemical.

AG-2000 Free Base is a bio-active chemical. Detailed information has not been published.

JMN13497 is an precursor compound to for synthesis of scytonemin. Scytonemin is a biological pigment synthesized by many strains of cyanobacteria, including Calothrix sp., Lyngbya aestuarii, and others. Scytonemin is also a potent PKL1 inhibitor, which inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in many cancel cells. Scytonemin was able to inhibit the proliferation of three myeloma cells in a dose-dependent manner, while U266 was the most sensitive one to scytonemin. Scytonemin , representing a novel Plk1 inhibitor, induced the inhibition of cell growth and cell cycle arrest in multiple myeloma cells by specifically decreasing Plk1 activity. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https: www.medkoo.com page naming).